TBI: Thorough Biomarker Investigation in Traumatic Brain Injury

Product:
Neurology, TBI
Topic:
Disease Area:
Sample Type:
Topic/Product:
Neurology, TBI
Disease Area:
Sample Type:

By: Geoffrey Feld, Ph.D. 
Geocyte LLC & Alamar Biosciences collaborator 

In 2015, the National Football League reached a settlement with former players that has paid over $1.5 billion in damages related to traumatic brain injury (TBI). More recently, Boston University’s CTE (chronic traumatic encephalopathy, the neurodegenerative disease linked to repeated trauma to the head) Center diagnosed CTE in 345 out of 376 former professional football players tested (91.7%).

Concussions in professional football have brought to light what researchers have been studying for decades: head trauma triggers neuroinflammation and degenerative pathways that, over time, can lead to dementia, mood problems, and premature death. TBI can affect humans of all walks of life: youth sports, car accidents, and combat and domestic violence victims. In the last decade, blood-based protein biomarkers have claimed center stage in diagnosing specific TBI physiology and uncovering new therapeutic avenues.

The NfL in NFL

TBI is not a single injury but a progressive, multi-phase disease that involves acute mechanical damage, secondary neuroinflammatory cascades, and long-term neurodegeneration (Hossain et al., 2024). Neuroimaging, particularly magnetic resonance imaging (MRI) and more widely available computed tomography (CT) scanning, has uncovered the structural changes associated with TBI, such as white matter loss and lesion volumes. However, in routine practice, these tools are not always accessible post-injury, and in the case of MRI, they are not practical for severely ill patients. Therefore, the clinical classification of TBI severity is still performed through the motor, eye, and verbal responses that comprise the Glasgow Coma Scale (GCS).

The GCS was originally developed for doctors to triage whether coma patients required surgery. It does not account for the underlying structural changes provided through imaging, nor does it encompass physiological changes associated with trauma (Chieregato et al., 2010). Clearly, diagnostic methods that better stratify patients based on brain damage are needed.

Reflective of the heterogeneous pathophysiology, several blood-based protein biomarkers with different biological roles are emerging, showing translational and clinical value (Hossain et al., 2024):

  • Glial fibrillary acidic protein (GFAP): a marker of glial (neuroinflammatory) activation
  • Ubiquitin C-terminal hydrolase-L1 (UCH-L1): a marker of proteasomal pathway degradation
  • S100B: calcium-binding protein associated with CNS astrocytes and an indicator of blood-brain barrier damage
  • Neurofilament light chain (NfL): expressed in axons and considered a marker of axonal injury
  • Total tau: a microtubule stabilization protein that becomes hyperphosphorylated in CNS diseases

While immunoassays sensitive enough to measure these proteins in blood are on the market, evidence suggests that multiplexing important TBI-associated proteins along with other CNS and inflammatory markers provides significant research value greater than the sum of the parts.

Deciphering brain-specific injury from other trauma

Dr. David M. Sharp leads the UK DRI Centre for Care Research & Technology at Imperial College London, and his research focuses on uniting neuroimaging, cogitative neuroscience, and biomarkers to improve the lives of those living with dementia and brain injury. A recent publication in Brain, spearheaded by clinical lecturer Dr. Lucia Li, elegantly unifies MRI neuroimaging and blood-based proteomics using the NULISAseq CNS Disease Panel 120 (Li et al., 2024).

What made the study so remarkable was the combination of deep MRI data for TBI patients and uninjured controls with a third study arm: individuals with non-TBI trauma (NTT, e.g., broken arm resulting from a fall). Armed with multifaceted CNS proteomics, neuroimaging, and a negative control, Li et al identified 16 diverse proteins specifically associated with TBI, including the usual suspects (UCH-L1, GFAP, S100), known and novel neurodegenerative markers (pTau231, total phosphorylated tau, Aβ42, PSEN1, YWHAG), and inflammatory (IL16, FCN2), as well as injury-related proteins exacerbated by TBI (IL1b, IL33, IL6, ENO2, and NfL).

“[The CNS Panel] has bits and pieces of various pathways, so you get a comprehensive survey of the CNS biology,” Dr. Li told the Alamar commercial team on a science call.

Now, for the juicy part. TBI results in increased lesion volume and reduced white matter scores by two different methods in subacute MRI (whole skeleton and corpus callosum mean fractional anisotropy, FA). Of the 16 TBI-associated plasma proteins, four are significantly associated with lesion volume (UCH-L1, total pTau, PSEN1), one with whole skeleton FA (SQSTM1, an autophagy marker), and one with corpus callosum FA (CCL2, a chemokine).

It doesn’t end there. The group used unsupervised clustering of differentially expressed proteins to reveal five distinct subgroups of individuals: two mainly consisting of controls and NTT, and three almost exclusively of TBI. These three groups exhibited different underlying biology (e.g., neuroinflammatory signatures) and imaging characteristics (e.g., focal injury burden, lesion volumes, and white matter FA).

Thus, the NULISAseq CNS Disease Panel captures brain structure and function, which could represent a surrogate for expensive and often impractical neuroimaging, at least as a triage tool.

The two-way street of preclinical models and clinical diagnostics

Due to disease complexity, challenges in neuroimaging both immediately and long after injury, and obvious ethical considerations, much of the progress in TBI research in vivo is based on preclinical mouse models. Researchers can control the severity, duration, and mechanism of injury using mice as surrogates (Fesharaki-Zadeh and Datta, 2024). Novel injury models include:

  • The close-head impact model of engineered rotational acceleration (CHIMERA) was developed to simulate mild TBI.
  • The closed-head projectile concussive impact model (PCI), developed at the Walter Reed Army Institute of Research, enables stringent control of impact mechanics.

Many validated protein biomarkers discussed (e.g., GFAP and UCH-L1) readily translate between humans and mice. Even though advances in high-dimensional proteomics are enabling unprecedented biomarker discovery in humans first, it is still important to evaluate specific roles for intriguing signatures in murine models and establish mechanisms. Likewise, measuring the same proteins found to be significant in human TBI in preclinical models validates the translatability of the models and thus supports the mechanistic understanding they can provide.

Alamar recently launched a comprehensive mouse panel that contains many of the same important CNS Disease Panel 120 human targets and their murine homologues. World-renowned TBI specialist Dr. Charyl Wellington at the University of British Columbia tested the NULISAseq Mouse Panel 120 in a TBI murine model and found similar differentially expressed proteins among injured and sham groups as Li et al. reported in humans. Tune into Dr. Wellington’s presentation of the data in a webinar later this month.  View On Demand.

By offering well-curated multiplex panels tailored to human and mouse CNS disease with industry-leading sensitivity, NULISAseq provides researchers a unique and essential ability to demonstrate the translatability of TBI-related protein signatures.  

Dr. Diaz-Arrastia presents at the 15th Annual Traumatic Brain Injury Conference in Boston, MA. Dr. Diaz-Arrastia is the Presidential Professor of Neurology and the Director of Clinical TBI Research at the University of Pennsylvania.

The future: immediate blood spot collection

Dr. Li and colleagues showed how ultra-sensitive, multiplexed proteomics in blood can capture TBI-dependent biological signatures, including inflammation, neurodegeneration, metabolism, blood-brain barrier integrity, and autophagy, as well as brain structural changes revealed with neuroimaging. Future validation can also explore the feasibility of measuring these signals using dried-blood and dried-plasma microsampling devices, which can provide robust NULISAseq data, despite their low volumes and low abundance targets.

We’re one step closer to diagnosing traumatic head injury at the site of the accident, whether on the sidelines, road shoulders, crime scene, or battlefield.

References

Chieregato, A. et al. (2010) “Classification of a traumatic brain injury: the Glasgow Coma scale is not enough,” Acta Anaesthesiologica Scandinavica, 54(6), pp. 696–702. Available at: https://doi.org/10.1111/J.1399-6576.2010.02234.X.

Fesharaki-Zadeh, A. and Datta, D. (2024) “An overview of preclinical models of traumatic brain injury (TBI): relevance to pathophysiological mechanisms,” Frontiers in Cellular Neuroscience, 18, p. 1371213. Available at: https://doi.org/10.3389/FNCEL.2024.1371213/XML/NLM.

Hossain, I. et al. (2024) “Blood biomarkers for traumatic brain injury: A narrative review of current evidence,” Brain and Spine, 4, p. 102735. Available at: https://doi.org/10.1016/J.BAS.2023.102735.

Li, L.M. et al. (2024) “High-dimensional proteomic analysis for pathophysiological classification of traumatic brain injury,” Brain, p. awae305. Available at:  https://doi.org/10.1093/brain/awae305/7775599.

Steve Williams, MD, PhD

CSO

Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.

Justin McAnear

CFO

Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition.  He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.